Anbio Biotechnology
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 22.2
- Dividend yield
- –
About Anbio Biotechnology
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Anbio Biotechnology is a biotechnology company that designs and supplies in vitro diagnostic (IVD) solutions, including instruments, assays, reagents, and retail self-test products. Its offerings span testing technologies such as fluorescent immunoassay (FIA), chemiluminescent immunoassay (ChLIA), molecular testing, dry chemistry, and lateral flow immunoassay (LFIA). These diagnostic solutions address respiratory conditions, COVID-19, and various non-respiratory health indications. The company sells to consumers, healthcare providers, health systems, enterprises, and governmental procurement bodies.
Anbio Biotechnology conducts operations primarily across European markets and sells its products globally, supported by CE markings and regional regulatory authorizations. The company engages third-party laboratories and manufacturers for research and production, relying on two key suppliers and a small group of key customers for a significant share of its business. The company maintains its principal executive offices in Frankfurt am Main, Germany.
Summary of the business section of Anbio Biotechnology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Anbio Biotechnology
- Founded
- 2021
- Headquarters
- Frankfurt Am Main, 2M
- Address
- Friedrich-Ebert-Anlage 49 60308
- Phone
- 4916096247281
- Website
- exchangerates.org.uk
- Employees
- 27, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- GGF CPA LTD, Guangzhou PRC
Stock & identifiers
- Ticker
- NNNN
- Exchange
- Nasdaq
- IPO date
- Feb 19, 2025
- Shares outstanding
- 144M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1982708
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Lau | CEO | – |
| Chris Tian | CBO | – |
| Suki Song | CFO | – |
| Michael W.C Zhang | Director | – |
| David H. Hsu | Director | – |
| Cany Xu | Director | – |
| Nancy Hartzler | Director | – |
Employees
Headcount reported in annual reports
“As of the date of this annual report, we have 27 staff members including full time employees and contractors on an as needed basis.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 19, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 14, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |